Recolony focuses on the development of cancer therapies based on microbial-derived products. These drugs have an enormous influence on our immune system, enhancing an immune reaction against cancer. With this approach, Recolony will develop a new class of drugs for the treatment of cancer.
Products, services, technology
RCLBP01: Live Biotherapeutic Product for the treatment of colorectal cancer and other types of solid tumors.
RCLM01: Microbial-derived metabolite for the treatment of solid tumors.
RCLB01: Biomarker for early detection of CRC and therapy efficacy
- http://www.recolony.ch
- +41 44 632 87 41
- info@recolony.ch
- Ana Montalban-Arques
